Worldquant Millennium Advisors LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 158,181 shares of the insurance provider's stock, valued at approximately $50,102,000. Worldquant Millennium Advisors LLC owned about 0.13% of Humana as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Creative Financial Designs Inc. ADV grew its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. CarsonAllaria Wealth Management Ltd. grew its holdings in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in Humana during the 3rd quarter worth approximately $29,000. Ashton Thomas Securities LLC bought a new position in Humana in the 3rd quarter valued at approximately $31,000. Finally, Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Humana Stock Performance
Shares of NYSE HUM traded down $1.33 during trading on Friday, reaching $281.73. 1,751,061 shares of the stock traded hands, compared to its average volume of 1,590,764. The company has a 50-day moving average of $273.44 and a 200-day moving average of $327.75. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $488.89. The stock has a market capitalization of $33.92 billion, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 2.27 and a beta of 0.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts forecast that Humana Inc. will post 16.14 EPS for the current fiscal year.
Humana Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. Humana's dividend payout ratio is currently 31.36%.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the stock. Oppenheimer lowered their price target on shares of Humana from $400.00 to $280.00 and set an "outperform" rating for the company in a report on Thursday, October 3rd. Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a "hold" rating on the stock in a research note on Thursday, October 3rd. Bank of America raised Humana from an "underperform" rating to a "neutral" rating and upped their price objective for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. TD Cowen boosted their target price on shares of Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Humana from $332.00 to $396.00 and gave the stock a "neutral" rating in a report on Wednesday, August 21st. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $315.86.
Get Our Latest Stock Report on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
